Gastroenterology
Achalasia
7
Pipeline Programs↗
5
Active Trials↗
4
Companies Involved↗
Achalasia is an early-stage landscape with 7 programs across 4 companies. The most active players are Astellas, Cyclerion Therapeutics, Milestone Pharmaceuticals Inc.. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 11
Phase 21
Phase 3
No programs
Analysis
Trial Status
12
clinical trials
Terminated2 · 17%
Unknown status2 · 17%
Recruiting2 · 17%
Withdrawn2 · 17%
Enrolling by invitation1 · 8%
Completed1 · 8%
Other2 · 17%
Clinical Trials
Trial Activity
12 trials
Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia
Recruiting·—·N/A·NCT05899842·132 enrolled
Corticosteroid Effect on Achalasia Variant EGJOO
Active, not recruiting·—·Phase 1·NCT06588348·12 enrolled
Single-Versus Multiple-dose Antimicrobial Prophylaxis for Peroral Endoscopic Myotomy in Achalasia
Unknown status·—·Phase 3·NCT03784365·40 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)